☆ 4.7 Article

Comparing Results of Five SARS-CoV-2 Antibody Assays Before and After the First Dose of ChAdOx1 nCoV-19 Vaccine among Health Care Workers

JOURNAL OF CLINICAL MICROBIOLOGY (2021)

Related references

Note: Only part of the references are listed.

Editorial Material Medicine, General & Internal

Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine

Tom Shimabukuro et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Article Microbiology

Comparison of Antibody Class-Specific SARS-CoV-2 Serologies for the Diagnosis of Acute COVID-19

Hans Verkerke et al.

Summary: Accurate diagnosis of acute severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is crucial for proper management of patients. Laboratory-developed class-specific clinical serology was found to have higher sensitivity and specificity in diagnosing SARS-CoV-2 infection in hospitalized patients, with IgA performing the best, especially in the early stages of infection.

JOURNAL OF CLINICAL MICROBIOLOGY (2021)

Add to Collection

Article Microbiology

Quantitative Measurement of Anti-SARS-CoV-2 Antibodies: Analytical and Clinical Evaluation

Victoria Higgins et al.

Summary: A study evaluating the quantitative Roche Elecsys anti-SARS-CoV-2 S assay showed high sensitivity, specificity, and positive predictive value in detecting SARS-CoV-2 antibodies post-infection. The study also demonstrated the assay's highest sensitivity at 15 to 30 days post-KR positivity and varying negative predictive values at different time points post-PCR positivity.

JOURNAL OF CLINICAL MICROBIOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Merryn Voysey et al.

Summary: The ChAdOx1 nCoV-19 vaccine has been shown to have an acceptable safety profile and effectiveness against symptomatic COVID-19, with higher efficacy observed in the group that received a low dose followed by a standard dose.

LANCET (2021)

Add to Collection

Article Microbiology

A New SARS-CoV-2 Dual-Purpose Serology Test: Highly Accurate Infection Tracing and Neutralizing Antibody Response Detection

Sean C. Taylor et al.

Summary: The cPass surrogate virus neutralization test (sVNT) is a highly accurate tool for monitoring SARS-CoV-2 immunity, providing valuable assistance in surveillance of infected/recovered and/or vaccinated individuals, as well as in drug and convalescent-phase donor screening. The data also suggest potential applications for calibrating live-cell neutralization tests and longitudinal testing of recovered and/or vaccinated patients.

JOURNAL OF CLINICAL MICROBIOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

Merryn Voysey et al.

Summary: The AZD1222 vaccine has been approved for emergency use in the UK with an interval of 4-12 weeks between doses. Analysis shows that the vaccine is efficacious with two doses and provides immunoprotection after the first dose before the second dose is administered.

LANCET (2021)

Add to Collection

Letter Respiratory System

Vaccination against COVID-19: insight from arterial and venous thrombosis occurrence using data from VigiBase

David M. Smadja et al.

EUROPEAN RESPIRATORY JOURNAL (2021)

Add to Collection

Article Hematology

Thrombocytopenia with acute ischemic stroke and bleeding in a patient newly vaccinated with an adenoviral vector-based COVID-19 vaccine

Rolf Ankerlund Blauenfeldt et al.

Summary: This study reported the first Danish case of presumed inflammatory and thrombotic response following vaccination with the AZD1222 COVID-19 vaccine. The patient, a 60-year-old woman, experienced abdominal pain 7 days after vaccination, along with adrenal hemorrhages, ischemic stroke, and ultimately death. Blood tests revealed significant drops in platelet counts and increased D-dimer levels, suggesting a novel immune-mediated response to the vaccine.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2021)

Add to Collection

Article Medicine, General & Internal

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial

Katherine R. W. Emary et al.

Summary: A post-hoc analysis was conducted on the efficacy of the ChAdOx1 nCoV-19 vaccine against the B.1.1.7 variant of SARS-CoV-2 in the UK. The vaccine showed reduced neutralisation activity against the B.1.1.7 variant in vitro, but still demonstrated efficacy against the B.1.1.7 variant of the virus.

LANCET (2021)

Add to Collection

Article Medicine, General & Internal

Comparison of Serologic Response of Hospitalized COVID-19 Patients Using 8 Immunoassays

Sun Min Lee et al.

Summary: The study in Korea highlighted discrepancies in antibody detection for SARS-CoV-2 using different immunoassay kits, indicating the need for caution when relying on results from a single immunoassay for both infection detection and immunologic status assessment.

JOURNAL OF KOREAN MEDICAL SCIENCE (2021)

Add to Collection

Article Medicine, General & Internal

COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study

Lennard Y. W. Lee et al.

LANCET (2020)

Add to Collection

Article Critical Care Medicine

Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy

Peter M. George et al.

LANCET RESPIRATORY MEDICINE (2020)

Add to Collection

Article Medicine, General & Internal

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial

Feng-Cai Zhu et al.

LANCET (2020)

Add to Collection

Article Medicine, General & Internal

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Pedro M. Folegatti et al.

LANCET (2020)

Add to Collection

Article Medicine, General & Internal

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

Denis Y. Logunov et al.

LANCET (2020)

Add to Collection

Article Immunology

Validation and clinical evaluation of a SARS-CoV-2 surrogate virus neutralisation test (sVNT)

Benjamin Meyer et al.

EMERGING MICROBES & INFECTIONS (2020)

Add to Collection

Article Medicine, General & Internal

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

Maheshi N. Ramasamy et al.

LANCET (2020)

Add to Collection

Article Medicine, General & Internal

Seroprevalence of Anti-SARS-CoV-2 Antibodies among Outpatients in Southwestern Seoul, Korea

Ji Yun Noh et al.

JOURNAL OF KOREAN MEDICAL SCIENCE (2020)

Add to Collection

Article Immunology

Multicenter evaluation of two chemiluminescence and three lateral flow immunoassays for the diagnosis of COVID-19 and assessment of antibody dynamic responses to SARS-CoV-2 in Taiwan

Shey-Ying Chen et al.

EMERGING MICROBES & INFECTIONS (2020)

Add to Collection

© Peeref 2019-2024. All rights reserved.